Navigation Links
QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
Date:1/9/2012

h are increasingly guiding the treatment decisions in various cancers and other diseases," said Peer Schatz, Chief Executive Officer of QIAGEN. "The two agreements announced today add to our portfolio the ALK biomarker, which is being targeted by several pharmaceutical companies for new anti-cancer treatments, as well as the IDH1/IDH2 biomarker, which is currently playing a critical role in intense R&D activity for candidate medicines targeting brain gliomas and other cancers. In addition to providing these assays to researchers, we intend to develop companion diagnostics to make these biomarkers available in combination with new medicines."

The strategic co-development partnership and licensing agreement with Insight Genetics, a molecular diagnostics company focused on enhancing personalized cancer care, gives QIAGEN worldwide exclusive rights to Insight Genetics' diagnostic IP to the ALK gene. The companies will collaborate in the development of a corresponding test that can be clinically validated and marketed by QIAGEN as a companion diagnostic. Mutations of ALK are implicated in non-small cell lung cancer (NSCLC) and other cancers, and several anticancer compounds known as ALK inhibitors, are in clinical trials. One ALK inhibitor has been approved by the FDA, but it is currently paired with a diagnostic method that can be technically challenging and costly.

Through its 89% subsidiary Ipsogen S.A., QIAGEN gained exclusive rights to diagnostics for IDH1/IDH2 mutations from Personal Genome Diagnostics Inc., a biotechnology company founded by experts in cancer genetics. In 2008, those scientists reported the discovery of mutations in IDH1/IDH2 in connection with brain cancers, including early-stage and late-stage gliomas. Subsequent studies have implicated IDH1/IDH2 mutations in AML and other cancers. Assays that detect and measure the biomarker could prove valuable for research into these diseases, differential diagnosis, and development of
'/>"/>

SOURCE QIAGEN N.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. SciQuest Announces Strategic Alliance with QIAGEN
2. QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations
3. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
4. QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata
5. Plexus Awarded Development Contract With QIAGEN
6. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11
7. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
8. QIAGEN Acquires Exclusive Licence for Key PI3K gene
9. QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests
10. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
11. QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... electricity, to move data would consume much less ... concern as chips, transistor counts rise. , Of ... light emitters, modulators, and detectors emitters are ... for optical chips is molybdenum disulfide (MoS2), which ... single, atom-thick layer. Other experimental on-chip light emitters ...
(Date:9/19/2014)... September 19, 2014 Biotech companies ... of emerging drug systems and advanced Laboratory Instrumentation. Companies ... Company (NYSE: BDX ), Thermo Fisher Scientific ... (NASDAQ: RGDO ), Sangamo Biosciences Inc. (NASDAQ: ... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or ...
(Date:9/19/2014)... September 19, 2014 BioTech News ... patents and results of studies and trials.  Companies in ... Company (NYSE: LLY ), Gilead Sciences Inc. ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) ... developing prodrug therapeutics for the treatment of cancer, announced ...
(Date:9/19/2014)... 2014 Dublin ... has announced the addition of the  "Micro Market ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... the fastest-growing segments in the chromatography market. The ... and expected to reach $2.0 billion by 2019, ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7Micro Market Monitor : Global Pre-packed Chromatography Columns 2
... Maxygen, Inc. (Nasdaq: MAXY ) that it has ... also known as R7025.,MAXY-alpha is a novel interferon-alpha for ... and is licensed to Roche. Preliminary observations from ... the pharmacodynamic and pharmacokinetic effects of,MAXY-alpha occurred in the ...
... ITMN ) today announced the pricing of its ... stock at a price to the,public of $19.50 per ... purchase up to an additional 525,000 shares of common,stock. ... sold by InterMune. Goldman, Sachs & Co. is ...
... YORK, Sept. 21 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ... to,the Company,s Board of Directors. Mr. Tarnok, 53, ... with extensive pharmaceutical industry experience in a wide,range of ... career at,Pfizer Inc., which he joined in 1989 as ...
Cached Biology Technology:Maxygen Announces Hold on MAXY-alpha Development Program 2Maxygen Announces Hold on MAXY-alpha Development Program 3InterMune Announces Pricing of $68 Million Public Offering of Common Stock 2Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors 2
(Date:9/18/2014)... and nitrogen comprise all spheres of our planet. ... caused imbalances and perturbations that resulted in increases ... result in climate changes which influence the complex ... atmosphere. Understanding these feedback mechanisms has become an ... during the past three decades. , In parallel, ...
(Date:9/18/2014)... that when people are too stressed they are often ... Brain Mind Institute (BMI) at EPFL have just highlighted ... chronic stress and the loss of social skills and ... a synaptic regulatory molecule in the brain. This was ... . , Carmen Sandi,s team went to look ...
(Date:9/18/2014)... probably the ultimate form of camouflage: you don,t just ... strategy is not as uncommon as you might think. ... USA, explains that the larval life stages of many ... of the anatomy that most creatures cannot make transparent. ... to shield each individual eye unit with an opaque ...
Breaking Biology News(10 mins):Greenhouse gas research enters a new era 2How stress tears us apart 2Transparent larvae hide opaque eyes behind reflections 2
... chronic stress day after day can produce wear and tear ... detrimental effect on learning and emotion. However, acute stress ... memory. Researchers at the University at Buffalo have shown, ... stress can produce a beneficial effect on learning and memory, ...
... and their colleagues have identified the gene that is mutated ... paraganglioma (PGL). The gene, called hSDH5, is required for activation ... the chemical reactions that take place within cells to convert ... in the journal Science , to be released online ...
... , , , ... recent analysis of the automated optical inspection (AOI) equipment market, ... & Sullivan Award for Product Innovation of the Year for ... system combines high-speed inspection with superior performance, accuracy, quality, and ...
Cached Biology News:Short stressful events may improve working memory 2Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 2Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 3Frost & Sullivan Recognizes MIRTEC With the 2009 Award for Automated Optical Inspection Product Innovation of the Year 2Frost & Sullivan Recognizes MIRTEC With the 2009 Award for Automated Optical Inspection Product Innovation of the Year 3
... The EC570-90 is a compact, lightweight, high ... 500 volts or 2500 milliamps. It is an ... RNA submarine gels. It is also ideal for ... time can be set to automatically end a ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
QCPN...
Rat Aortic Smooth Muscle Cells (RAOSMC) (>500,000 cells)...
Biology Products: